These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Biosynthesis and biodegradation of GM2 ganglioside]. Hirabayashi Y; Kasakura H; Matsumoto M Tanpakushitsu Kakusan Koso; 1984 Sep; 29(9):708-22. PubMed ID: 6240072 [No Abstract] [Full Text] [Related]
23. Assay of the GM2-ganglioside cleaving hexosaminidase activity of skin fibroblasts for GM2-gangliosidoses. Harzer K Clin Chim Acta; 1983 Nov; 135(1):89-93. PubMed ID: 6228344 [No Abstract] [Full Text] [Related]
24. [Genetic deficiencies of beta-N-acetylhexosaminidase A and B: Tay-Sachs and Sandhoff diseases (GM2-gangliosidosis)]. Suzuki K Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):721-7. PubMed ID: 2978703 [No Abstract] [Full Text] [Related]
25. Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Myerowitz R; Lawson D; Mizukami H; Mi Y; Tifft CJ; Proia RL Hum Mol Genet; 2002 May; 11(11):1343-50. PubMed ID: 12019216 [TBL] [Abstract][Full Text] [Related]
26. Identification of an active acidic residue in the catalytic site of beta-hexosaminidase. Tse R; Vavougios G; Hou Y; Mahuran DJ Biochemistry; 1996 Jun; 35(23):7599-607. PubMed ID: 8652542 [TBL] [Abstract][Full Text] [Related]
27. Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Chamoles NA; Blanco M; Gaggioli D; Casentini C Clin Chim Acta; 2002 Apr; 318(1-2):133-7. PubMed ID: 11880123 [TBL] [Abstract][Full Text] [Related]
28. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Platt FM; Neises GR; Reinkensmeier G; Townsend MJ; Perry VH; Proia RL; Winchester B; Dwek RA; Butters TD Science; 1997 Apr; 276(5311):428-31. PubMed ID: 9103204 [TBL] [Abstract][Full Text] [Related]
29. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis]. Tsuji D Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522 [TBL] [Abstract][Full Text] [Related]
30. Biochemistry and genetics of Tay-Sachs disease. Gravel RA; Triggs-Raine BL; Mahuran DJ Can J Neurol Sci; 1991 Aug; 18(3 Suppl):419-23. PubMed ID: 1834320 [TBL] [Abstract][Full Text] [Related]
31. Two small deletion mutations of the HEXB gene are present in DNA from a patient with infantile Sandhoff disease. McInnes B; Brown CA; Mahuran DJ Biochim Biophys Acta; 1992 Apr; 1138(4):315-7. PubMed ID: 1532910 [TBL] [Abstract][Full Text] [Related]
32. Central nervous system therapy for lysosomal storage disorders. Enns GM; Huhn SL Neurosurg Focus; 2008; 24(3-4):E12. PubMed ID: 18341388 [TBL] [Abstract][Full Text] [Related]
33. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice. Itakura T; Kuroki A; Ishibashi Y; Tsuji D; Kawashita E; Higashine Y; Sakuraba H; Yamanaka S; Itoh K Biol Pharm Bull; 2006 Aug; 29(8):1564-9. PubMed ID: 16880605 [TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus transformed lymphoid cell lines as a new model system in culture for the study of GM2-gangliosidoses: Tay-Sachs and Sandhoff diseases. Maret A; Salvayre R; Negre A; Bes JC; Douste-Blazy L Biol Cell; 1985; 53(3):293-6. PubMed ID: 2990625 [TBL] [Abstract][Full Text] [Related]
36. New blood cells help an overburdened brain. Mattson MP Trends Neurosci; 2001 Jan; 24(1):5. PubMed ID: 11163874 [No Abstract] [Full Text] [Related]
37. Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Yamanaka S; Johnson MD; Grinberg A; Westphal H; Crawley JN; Taniike M; Suzuki K; Proia RL Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9975-9. PubMed ID: 7937929 [TBL] [Abstract][Full Text] [Related]